Papillary Renal Cell Carcinoma — Trials

Papillary Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

32 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–14 of 14 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07024680	Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC(PRCC)	completed	—	48	AstraZenecaINDUSTRY	1	Sep 25, 2026	clinicaltrials
NCT06339138	Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study	completed	—	589	Mayo ClinicOTHER